Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.54 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 5/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397726 | 1.00 | TTBK1 (0.54) | TTBK1TTBK2JAK2JAK3NOTUM | |
| SCHEMBL16359822 | 0.76 | TTBK1 (0.42) | TTBK1TTBK2JAK2JAK3NOTUM | |
| SCHEMBL29407654 | 0.76 | JAK2 (0.53) | TTBK1TTBK2JAK2JAK3TRPA1 | |
| SCHEMBL39050 | 0.76 | JAK2 (0.53) | TTBK1TTBK2JAK2JAK3TRPA1 | |
| SCHEMBL24345975 | 0.75 | AKT2 (0.50) | TTBK1TTBK2JAK2JAK3NOTUM | |
| SCHEMBL1085771 | 0.74 | PRKCI (0.53) | TTBK1TTBK2JAK2JAK3TRPA1 | |
| SCHEMBL12997948 | 0.74 | JAK2 (0.52) | TTBK1TTBK2JAK2JAK3TRPA1 | |
| SCHEMBL102201 | 0.74 | TTBK1 (0.54) | TTBK1TTBK2JAK2JAK3TRPA1 | |
| Hydrochloric Acid SCHEMBL7018150 | 0.74 | JAK2 (0.52) | TTBK1TTBK2JAK2JAK3TRPA1 | |
| SCHEMBL2678646 | 0.74 | JAK2 (0.52) | TTBK1TTBK2JAK2JAK3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472169-B1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED NANTONG PHARMACEUTICALS CO LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | claimed |
| CN-109563098-B | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines | 斯福瑞（南通）制药有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-112645956-A | Preparation method of prodrug intermediate of thymidine phosphorylase inhibitor | 天津全和诚科技有限责任公司 | 2021-04-13 | — | — | CN | claimed |
| CN-111533748-A | Method for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine by adopting non-phosphorus chlorination reagent | 江苏恒沛药物科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| US-10738058-B2 | Method of manufacturing 4-chloro-7H-pyrrolo[2,3-D]pyrimidine | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2020-08-11 | — | — | US | claimed |
| CN-111349100-A | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 安徽大学 | 2020-06-30 | — | — | CN | claimed |
| CN-107722012-B | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines | 斯福瑞（南通）制药有限公司 | 2020-05-29 | — | — | CN | claimed |
| CN-107827893-B | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 常州齐晖药业有限公司 | 2020-03-27 | — | — | CN | claimed |
| CN-110790768-A | Production system of medical intermediate 4-chloro-pyrrolopyrimidine | 廖文杰 | 2020-02-14 | — | — | CN | claimed |
| US-20190169200-A1 | NOVEL METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2019-06-06 | — | — | US | claimed |
| EP-3472169-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | Siegfried (Nantong) Pharmaceuticals Co. Ltd. (CN) | 2019-04-24 | — | — | EP | claimed |
| WO-2018029641-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2018-02-15 | — | — | WO | claimed |
| EP-0576211-B1 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | LILLY CO ELI (US) | 2001-08-22 | — | — | EP | claimed |
| EP-0595467-B1 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | LILLY CO ELI (US) | 2000-07-19 | — | — | EP | claimed |
| US-5426187-A | Process for the preparation of 4-hydroxy-5-substituted ethynylpyrrolo [2,3-d]pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| EP-0595467-A2 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | ELI LILLY AND COMPANY (US) | 1994-05-04 | — | — | EP | claimed |
| US-5278307-A | Process for preparing 4-hydroxypyrrolo(2,3-d)pyrimidine based antifolate compounds and intermediates | ELI LILLY AND COMPANY (US) | 1994-01-11 | — | — | US | claimed |
| EP-0576211-A2 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | claimed |
| JP-6056838-A | — | — | None | — | — | JP | disclosed |
| JP-6211863-A | — | — | None | — | — | JP | disclosed |
| US-20260042768-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12479851-B2 | Process and intermediates for preparing a JAK inhibitor | INCYTE CORPORATION (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12428426-B2 | Process and intermediates for preparing a JAK1 inhibitor | INCYTE CORPORATION (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240368171-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| CN-108395433-B | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2024-10-22 | — | — | CN | disclosed |
| US-12071439-B2 | Process and intermediates for preparing a JAK inhibitor | INCYTE CORPORATION (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240246982-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION | 2024-07-25 | — | — | US | disclosed |
| CN-118317946-A | Processes and intermediates for the preparation of baratinib | 因赛特公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240166655-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2024-05-23 | — | — | US | disclosed |
| EP-4370504-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4341264-A1 | PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS | Drugs for Neglected Diseases Initiative (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11905292-B2 | Process and intermediates for preparing a JAK inhibitor | INCYTE CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-11897889-B2 | Process and intermediates for preparing a JAK1 inhibitor | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4200278-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | Incyte Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4200300-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | Incyte Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3472169-B1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED NANTONG PHARMACEUTICALS CO LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| EP-3472169-B1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED NANTONG PHARMACEUTICALS CO LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20230059389-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230059389-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| WO-2023001133-A1 | PRMT5 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023288197-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288197-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220056034-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-20220056034-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| WO-2022040172-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040180-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040180-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056035-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11078214-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-03 | — | — | US | disclosed |
| CN-109563098-B | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines | 斯福瑞（南通）制药有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-109563098-B | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines | 斯福瑞（南通）制药有限公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| CN-112645956-A | Preparation method of prodrug intermediate of thymidine phosphorylase inhibitor | 天津全和诚科技有限责任公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| CN-111533748-A | Method for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine by adopting non-phosphorus chlorination reagent | 江苏恒沛药物科技有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111533748-A | Method for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine by adopting non-phosphorus chlorination reagent | 江苏恒沛药物科技有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-10738058-B2 | Method of manufacturing 4-chloro-7H-pyrrolo[2,3-D]pyrimidine | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2020-08-11 | — | — | US | disclosed |
| US-10738058-B2 | Method of manufacturing 4-chloro-7H-pyrrolo[2,3-D]pyrimidine | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2020-08-11 | — | — | US | disclosed |
| US-10738058-B2 | Method of manufacturing 4-chloro-7H-pyrrolo[2,3-D]pyrimidine | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2020-08-11 | — | — | US | disclosed |
| CN-111349100-A | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 安徽大学 | 2020-06-30 | — | — | CN | disclosed |
| CN-111349100-A | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 安徽大学 | 2020-06-30 | — | — | CN | disclosed |
| CN-107722012-B | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines | 斯福瑞（南通）制药有限公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-107722012-B | Process for preparing 4-chloro-7H-pyrrolo [2,3-d ] pyrimidines | 斯福瑞（南通）制药有限公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-107827893-B | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 常州齐晖药业有限公司 | 2020-03-27 | — | — | CN | disclosed |
| CN-107827893-B | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine | 常州齐晖药业有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20200079788-A1 | MONOCYCLIC THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF SAME | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-03-12 | — | — | US | disclosed |
| CN-110790768-A | Production system of medical intermediate 4-chloro-pyrrolopyrimidine | 廖文杰 | 2020-02-14 | — | — | CN | disclosed |
| CN-110724145-A | Synthetic method of medical intermediate 4-chloropyrrolopyrimidine | 廖文杰 | 2020-01-24 | — | — | CN | disclosed |
| US-10457688-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-10-29 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190169200-A1 | NOVEL METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| US-20190169200-A1 | NOVEL METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| US-20190169200-A1 | NOVEL METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| EP-3472169-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | Siegfried (Nantong) Pharmaceuticals Co. Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| EP-3472169-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | Siegfried (Nantong) Pharmaceuticals Co. Ltd. (CN) | 2019-04-24 | — | — | EP | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-20180265520-A1 | MONOCYCLIC THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF SAME | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180237442-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2018-08-23 | — | — | US | disclosed |
| US-9994586-B2 | Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-12 | — | — | US | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2018029641-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018029641-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018029641-A1 | METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-d]PYRIMIDINE | SIEGFRIED (NANTONG) PHARMACEUTICALS CO. LTD. (CN) | 2018-02-15 | — | — | WO | disclosed |
| EP-3272738-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-2398774-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017031176-A1 | MONOCYCLIC, THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF THE SAME | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050978-A1 | Monocyclic, Thieno, Pyrido, and Pyrrolo Pyrimidine Compounds and Methods of Use and Manufacture of the Same | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-02-23 | — | — | US | disclosed |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2016-09-08 | — | — | US | disclosed |
| CN-105906631-A | Compounds and methods for kinase modulation, and indications therefor | 普莱希科公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20160177271-A1 | COMBINATIONAL USE OF MECHANICAL MANIPULATION AND PROGRAMIN TO GENERATE PLURIPOTENT STEM CELLS FROM SOMATIC CELLS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2016-06-23 | — | — | US | disclosed |
| CN-105669675-A | Processes for preparing jak inhibitors and related intermediate compounds | 因西特控股公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-105669676-A | Processes for preparing jak inhibitors and related intermediate compounds | 因西特控股公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-105622616-A | Preparation method of 4-chloropyrrolo[2,3-d]pyrimidine | SHANGHAI ABA CHEMICALS CO LTD | 2016-06-01 | — | — | CN | disclosed |
| EP-3019505-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-9290506-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| CN-102348693-B | Methods for preparing JAK inhibitors and related intermediate compounds | INCYTE CORP. (US) | 2016-03-16 | — | — | CN | disclosed |
| EP-2188289-B1 | (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | LEXICON PHARMACEUTICALS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150218174-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2297153-B1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9000161-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-8993582-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| CN-104470926-A | Substituted pyrrolopyrimidines | Bayer Pharma AG | 2015-03-25 | — | — | CN | disclosed |
| WO-2015004024-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-8932881-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | GIRI BRIJ PAL (US) | 2015-01-13 | — | — | US | disclosed |
| US-8883806-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| EP-2272517-B1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-10-01 | — | — | EP | disclosed |
| EP-2272517-B1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-10-01 | — | — | EP | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-8809336-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8809336-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8809336-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8796293-B2 | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796293-B2 | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796293-B2 | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2674433-A1 | LIMK2 inhibitors, compositions comprising them and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-8546407-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8507672-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2597098-A1 | (7H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8450332-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8410265-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130012527-A1 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES | YALE UNIVERSITY (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-12-27 | — | — | US | disclosed |
| CN-102740698-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC | 2012-10-17 | — | — | CN | disclosed |
| EP-2501236-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8193202-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2426219-A1 | Riboswitches and methods and compositions for use of and with riboswitches | Yale University (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426218-A1 | Riboswitches and methods and compositions for use of and with riboswitches | Yale University (US) | 2012-03-07 | — | — | EP | disclosed |
| CN-102348693-A | Methods for preparing JAK inhibitors and related intermediate compounds | INCYTE CORP | 2012-02-08 | — | — | CN | disclosed |
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| CN-102171211-A | Piperidine derivatives useful as JAK3 inhibitors | BIOCRYST PHARM INC | 2011-08-31 | — | — | CN | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| EP-2324020-A2 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100286082-A1 | RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100152212-A1 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2164996-A2 | RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-10-22 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| CN-101479263-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| CN-101432287-A | Pyrrolopyrimidine derivatives as HSP90 inhibitors | VERNALIS R&D LTD (GB) | 2009-05-13 | — | — | CN | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2008156987-A9 | RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES | UNIV YALE (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090042893-A1 | KINASE INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-02-12 | — | — | US | disclosed |
| EP-2007767-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R&D) LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| EP-2004651-A2 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008156987-A2 | RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES | YALE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080214583-A1 | 7H-Pyrrolo[2,3-D]Pyrimidine Derivatives, As Well As Their Therapeutically Acceptable Salts, Pharmaceutical Preparations Containing Them And Process For Production The Active Agent | SZOLCSANYI JANOS | 2008-09-04 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | PFIZER INC | 2007-12-13 | — | — | US | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007115620-A2 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| EP-1812003-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007066189-A2 | SALTS, PRODRUGS AND FORMULATIONS OF 1-[5-(4-AMINO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONYL)-2-METHOXY-PHENYL]-3-(2,4-DICHLORO-PHENYL)-UREA | PFIZER PRODUCTS INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006046023-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| EP-1444982-A1 | The use of purine derivatives as selective kinase inhibitors | MERCKLE GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| EP-0576211-B1 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | LILLY CO ELI (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-0783505-B1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| EP-0595467-B1 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | LILLY CO ELI (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6066732-A | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| CN-1046731-C | Pyrrolo [2,3-d ] pyrimidines and their use | NOVARTIS AG (CH) | 1999-11-24 | — | — | CN | disclosed |
| CN-1164234-A | Pyrrolo [2, 3-d ] pyrimidines and their use | NOVARTIS AG (CH) | 1997-11-05 | — | — | CN | disclosed |
| EP-0795556-A1 | 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997032879-A1 | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| EP-0783505-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| EP-0549886-B1 | Process for the preparation of pyrrolo[2,3-d]pyrimidines | UNIV PRINCETON (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1996010028-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 1996-04-04 | — | — | WO | disclosed |
| EP-0432677-B1 | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives | UNIV PRINCETON (US) | 1996-03-06 | — | — | EP | disclosed |
| CN-1030608-C | N-(pyrrolo {2,3-d} pyrimidin-3-ylacyl)-glutamic acid derivatives | UNIV PRINCETON (US) | 1996-01-03 | — | — | CN | disclosed |
| US-5426187-A | Process for the preparation of 4-hydroxy-5-substituted ethynylpyrrolo [2,3-d]pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| US-5344932-A | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1994-09-06 | — | — | US | disclosed |
| JP-H06211863-A | PREPARATION OF ANTIFOLATE COMPOUND AND INTERMEDIATE THEREOF | ELI LILLY & CO | 1994-08-02 | — | — | JP | disclosed |
| EP-0595467-A2 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | ELI LILLY AND COMPANY (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0595467-A2 | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | ELI LILLY AND COMPANY (US) | 1994-05-04 | — | — | EP | disclosed |
| JP-H0656838-A | METHOD FOR SYNTHESIZING 4-HYDROXY-5-HALOPYRROLO(2,3-D)PYRIMIDINE | ELI LILLY & CO | 1994-03-01 | — | — | JP | disclosed |
| US-5278307-A | Process for preparing 4-hydroxypyrrolo(2,3-d)pyrimidine based antifolate compounds and intermediates | ELI LILLY AND COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| US-5278307-A | Process for preparing 4-hydroxypyrrolo(2,3-d)pyrimidine based antifolate compounds and intermediates | ELI LILLY AND COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| US-5278307-A | Process for preparing 4-hydroxypyrrolo(2,3-d)pyrimidine based antifolate compounds and intermediates | ELI LILLY AND COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0576211-A2 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| EP-0576211-A2 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5254687-A | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5248775-A | Pyrrolo(2,3-d)pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| US-5235053-A | Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| US-5235053-A | Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0549886-A1 | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0432677-A1 | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-06-19 | — | — | EP | disclosed |
| US-4996206-A | Antitumor agent | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-02-26 | — | — | US | disclosed |
| US-4996206-A | Antitumor agent | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897889-B2 | Process and intermediates for preparing a JAK1 inhibitor | JAK1, JAK2, JAK3 | TTBK1 1053/4885TTBK2 1615/4885JAK2 2/4885 |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | TTBK1 2069/4885TTBK2 2183/4885JAK2 2/4885 |
| US-20200079788-A1 | MONOCYCLIC THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF SAME | DPYD, TYMS, THPO | TTBK1 1222/4885TTBK2 959/4885JAK2 280/4885 |
| US-20090042893-A1 | KINASE INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, TNK2 | TTBK1 279/4885TTBK2 169/4885JAK2 408/4885 |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | TTBK1 2671/4885TTBK2 1778/4885JAK2 2515/4885 |
| US-20240246982-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | JAK1, JAK2, JAK3 | TTBK1 1053/4885TTBK2 1615/4885JAK2 2/4885 |
| US-20260042768-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | JAK1, JAK2, JAK3 | TTBK1 383/4885TTBK2 444/4885JAK2 2/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | TTBK1 761/4885TTBK2 797/4885JAK2 3/4885 |
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | TTBK1 74/4885TTBK2 120/4885JAK2 300/4885 |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-20100152212-A1 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES | NSUN3, TRDMT1, RPRD2 | TTBK1 3076/4885TTBK2 3281/4885JAK2 4441/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | TTBK1 548/4885TTBK2 708/4885JAK2 19/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-20240368171-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | JAK2, JAK1, JAK3 | TTBK1 832/4885TTBK2 762/4885JAK2 1/4885 |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | TTBK1 221/4885TTBK2 106/4885JAK2 766/4885 |
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | TTBK1 359/4885TTBK2 365/4885JAK2 70/4885 |
| US-20140107137-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK1, CDK2, CDK3 | TTBK1 384/4885TTBK2 305/4885JAK2 426/4885 |
| US-20150218174-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-20070287719-A1 | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea | CDKN1A, DPYD, SLC14A1 | TTBK1 2410/4885TTBK2 2621/4885JAK2 1331/4885 |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | TTBK1 770/4885TTBK2 1070/4885JAK2 72/4885 |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | TTBK1 338/4885TTBK2 251/4885JAK2 391/4885 |
| US-11905292-B2 | Process and intermediates for preparing a JAK inhibitor | JAK2, JAK1, JAK3 | TTBK1 1125/4885TTBK2 1170/4885JAK2 1/4885 |
| US-20100286082-A1 | RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES | RNGTT, NSUN3, RNASEH1 | TTBK1 3945/4885TTBK2 3735/4885JAK2 3021/4885 |
| US-20190169200-A1 | NOVEL METHOD OF MANUFACTURING 4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE | DPYD, DCTD, BCDIN3D | TTBK1 1540/4885TTBK2 1369/4885JAK2 1835/4885 |
| US-20130012527-A1 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES | RNASEH1, NSUN3, RNGTT | TTBK1 2960/4885TTBK2 3244/4885JAK2 4343/4885 |
| US-20240166655-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | JAK2, JAK1, JAK3 | TTBK1 1125/4885TTBK2 1170/4885JAK2 1/4885 |
| US-20080214583-A1 | 7H-Pyrrolo[2,3-D]Pyrimidine Derivatives, As Well As Their Therapeutically Acceptable Salts, Pharmaceutical Preparations Containing Them And Process For Production The Active Agent | TYMS, DPYD, P2RX7 | TTBK1 2391/4885TTBK2 1969/4885JAK2 726/4885 |
| US-20220056034-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | JAK1, JAK2, JAK3 | TTBK1 1053/4885TTBK2 1615/4885JAK2 2/4885 |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | CDK2, CDK1, CDK3 | TTBK1 384/4885TTBK2 299/4885JAK2 439/4885 |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | TTBK1 206/4885TTBK2 176/4885JAK2 258/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | TTBK1 969/4885TTBK2 884/4885JAK2 3/4885 |
| US-20180237442-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-12071439-B2 | Process and intermediates for preparing a JAK inhibitor | JAK2, JAK1, JAK3 | TTBK1 832/4885TTBK2 762/4885JAK2 1/4885 |
| US-20180265520-A1 | MONOCYCLIC THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF SAME | TYMS, CYP4F3, DPYD | TTBK1 2117/4885TTBK2 2350/4885JAK2 840/4885 |
| US-20220056035-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | JAK2, JAK1, JAK3 | TTBK1 1125/4885TTBK2 1170/4885JAK2 1/4885 |
| US-12428426-B2 | Process and intermediates for preparing a JAK1 inhibitor | JAK1, JAK2, JAK3 | TTBK1 1053/4885TTBK2 1615/4885JAK2 2/4885 |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, KRAS, RAF1 | TTBK1 770/4885TTBK2 1070/4885JAK2 72/4885 |
| US-20230059389-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | JAK2, JAK1, JAK3 | TTBK1 832/4885TTBK2 762/4885JAK2 1/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-12479851-B2 | Process and intermediates for preparing a JAK inhibitor | JAK2, JAK1, JAK3 | TTBK1 1125/4885TTBK2 1170/4885JAK2 1/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TTBK1 597/4885TTBK2 854/4885JAK2 1/4885 |
| US-11078214-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DPYD, TYMS, THPO | TTBK1 1222/4885TTBK2 959/4885JAK2 280/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | TTBK1 964/4885TTBK2 905/4885JAK2 3/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | TTBK1 548/4885TTBK2 708/4885JAK2 19/4885 |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | TTBK1 221/4885TTBK2 106/4885JAK2 766/4885 |
| US-10738058-B2 | Method of manufacturing 4-chloro-7H-pyrrolo[2,3-D]pyrimidine | DPYD, DCTD, APOBEC3B | TTBK1 1783/4885TTBK2 1471/4885JAK2 1636/4885 |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | TTBK1 724/4885TTBK2 623/4885JAK2 478/4885 |
| US-10457688-B2 | Monocyclic thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of same | DPYD, TPX2, TYMS | TTBK1 1825/4885TTBK2 943/4885JAK2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.